2020 American Transplant Congress
Three-Month Results of a Phase 2 Trial Evaluating Clazakizumab in Late Antibody-Mediated Rejection – Early Impact of Interleukin-6 Blockade on Donor-Specific Antibody Levels, Rejection Morphology and Gene Expression
*Purpose: Targeting Interleukin-6 (IL-6) is a promising strategy to counteract antibody-mediated rejection (ABMR). This phase 2 trial (NCT03444103) was designed to evaluate the safety and…2020 American Transplant Congress
New Strategy to Maximize Nanomedicine Delivery During Ex Vivo Organ Perfusion
*Purpose: Organ transplant is a highly successful therapy for patients facing end stage organ failure. However, there is a severe lack of transplantable organs which…2020 American Transplant Congress
Early Impact of Interleukin-6 Blockade on the Distribution of Peripheral Blood Immune Cell Subpopulations – 3-Month Results of a Phase 2 Trial Evaluating Clazakizumab in Late Antibody-Mediated Rejection
*Purpose: Interleukin-6 (IL-6) is considered to play a critical role within the multifacted pathophysiological process of antibody-mediated rejection (ABMR), including modulation of regulatory T cells…2020 American Transplant Congress
CD38 Antibody Daratumumab for the Treatment of Chronic Antibody-Mediated Kidney Allograft Rejection
*Purpose: Late antibody-mediated rejection (ABMR) is a major cause of transplant failure. Potential therapeutic targets are plasma cells (PC) and natural killer (NK) cells expressing…2020 American Transplant Congress
Long Term Outcomes of Kidney Transplantation in Patients with AL-Amyloidosis – The Mayo Clinic Experience
*Purpose: New clone-directed therapies and better definition of hematological response criteria allows assessment of post-kidney transplantation outcomes in patients with light-chain (AL) amyloidosis*Methods: Patients with…2020 American Transplant Congress
Renal Transplant Induction Therapy Safety Outcomes Comparison
*Purpose: Induction immunosuppression with alemtuzumab and rabbit anti-thymocyte globulin (r-ATG) reduces acute rejection following kidney transplantation. Efficacy is thought to be similar between the agents…2020 American Transplant Congress
Risk of Histological Relapse in Patients with Monoclonal Gammopathy of Renal Significance after Kidney Transplantation
*Purpose: There is increased recognition of Monoclonal Gammopathy of Renal Significance (MGRS) but data on kidney transplant (ktx)outcomes are lacking. We assessed KTX outcomes of…2020 American Transplant Congress
Pneumocystis Pneumonia Occurrence and Prophylaxis Duration in Kidney Transplant Recipients According to Perioperative Treatment with Rituximab
Department of Surgery, Division of Kidney and Pancreas Transplant, AMC, Seoul, Korea, Republic of
*Purpose: Pneumocystis pneumonia (PCP) is a life-threatening fungal infection that can occur in kidney transplantation (KT) recipients. A growing number of KT recipients are receiving…2019 American Transplant Congress
The Effects of Anti-BAFF Monoclonal Antibody in the HLA-A2 Sensitized Mouse Model
*Purpose: B-cell activating factor (BAFF) is a cytokine that plays a role in the survival, proliferation and differentiation of B-cells. The aim of this study…2019 American Transplant Congress
Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Solid Organ Transplant Recipients at an Academic Medical Center
Center for Transplantation, University of California, San Diego Health System, La Jolla, CA
*Purpose: In the United States, the incidence of Clostridium difficile infection (CDI) has increased remarkably and remains a significant burden in the solid organ transplant…